
Opinion|Videos|July 31, 2023
Choosing an Appropriate Treatment Regimen for Patients With Advanced Urothelial Carcinoma
Experts explain how they would choose between combination therapy regimens for patients with metastatic or locally advanced urothelial carcinoma if the choice of treatment was not influenced by low supply availability.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5







































